IPO
IPO filing, visualized

BirchBioMed Inc.

NasdaqCanadaS-1/A · Oct 9, 2026Filed

No price range yet · latest SEC filing Oct 9, 2026.

Pinch-zoom for details.

The offering

What the company does

Clinical-stage drug developer working on treatments for scarring (fibrosis).

Operating result

Fiscal year

1st half

Quarter

Net result

Fiscal year

1st half

Quarter

Things to weigh

  • Loss-making: net loss of $1.25M in H1 2026.

The numbers

$FY2024FY2025YoYH1 2025H1 2026ChangeQ 2024
Operating result(3.35M)(3.46M)−3.3%(1.20M)(1.19M)+0.5%(853K)
Net result(3.36M)(4.55M)−35.6%(1.41M)(1.25M)+11.4%(893K)
$FY2024FY2025YoY
Operating result(3.35M)(3.46M)−3.3%
Net result(3.36M)(4.55M)−35.6%
$H1 2025H1 2026Change
Operating result(1.20M)(1.19M)+0.5%
Net result(1.41M)(1.25M)+11.4%
$Q 2024
Operating result(853K)
Net result(893K)

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. Investing in our securities is highly speculative and involves a significant degree of risk
  2. We have a need for capital and will need to raise additional capital after the Direct Listing to continue to operate our business…
  3. Early indications of safety and tolerability results from our clinical studies with FS2 may not predict the results of later studies
  4. We have a limited operating history and a history of escalating operating losses and expect to incur significant additional operating losses
  5. The regulatory approval process is expensive, time consuming and uncertain…
  6. Due to the recent change in presidential administration in the U.S., we…

The filing's own risk-factor headings, shortened.

Strategy

  1. Scarring: Antifibrogenic refers to the reduction of fibrosis (pathologic scarring), which results from excessive production…
  2. Organ Fibrosis: Fibrosis affects all vital organs, and accounts for a staggering 45% of deaths worldwide with no effective therapies currently…
  3. Chronic Kidney Disease (CKD)
  4. Liver Fibrosis: Progressive deposition of ECM that destroys the physiological liver architecture is what defines liver fibrosis
  5. Pulmonary Fibrosis: PF can occur in association with a number of conditions and diseases, including environmental exposure (e.g., asbestos…

The filing's own strategy headings, shortened.

Source: BirchBioMed Inc.'s Form S-1/A, filed with the SEC on Oct 9, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.